We recently suggested a novel site-specific N-glycosylation mechanism in Trypanosoma brucei whereby some protein N-glycosylation sites selectively receive Man 9 GlcNAc 2 from Man 9 GlcNAc 2 -PP-Dol while others receive Man 5 GlcNAc 2 from Man 5 GlcNAc 2 -PP-Dol. In this paper, we test this model by creating procyclic and bloodstream form null mutants of TbALG3, the gene that encodes the α-mannosyltransferase that converts Man 5 GlcNAc 2 -PP-Dol to Man 6 GlcNAc 2 -PPDol. The procyclic and bloodstream form TbALG3 null mutants grow with normal kinetics, remain infectious to mice and tsetse flies, respectively, and have normal morphology. However, both forms display aberrant N-glycosylation of their major surface glycoproteins, procylcin, and variant surface glycoprotein, respectively. Specifically, procyclin and variant surface glycoprotein N-glycosylation sites that are modified with Man 9 GlcNAc 2 and processed no further than Man 5 GlcNAc 2 in the wild type are glycosylated less efficiently but processed to complex structures in the mutant. These data confirm our model and refine it by demonstrating that the biantennary glycan transferred from Man 5 GlcNAc 2 -PP-Dol is the only route to complex N-glycans in T. brucei and that Man 9 GlcNAc 2 -PP-Dol is strictly a precursor for oligomannose structures. The origins of site-specific Man 5 GlcNAc 2 or Man 9 GlcNAc 2 transfer are discussed and an updated model of N-glycosylation in T. brucei is presented.
Introduction
The trypanosmatid Trypanosoma brucei is a parasitic protozoan organism that causes nagana in cattle and human African sleeping sickness. The organism undergoes a complex life cycle, involving major biochemical and morphological changes, be-1 To whom correspondence should be addressed: Tel. +44-1382-384219; Fax +44-1382-348896; e-mail: m.a.j.ferguson@dundee.ac.uk tween its mammalian host and tsetse fly vector. These changes include complete remodeling of the major cell surface coat molecules.
The tsetse midgut-dwelling procyclic form of T. brucei has a surface coat of 3 × 10 6 polyanionic, rod-like, procyclin glycoproteins (Mowatt and Clayton 1987; Roditi et al. 1987 Roditi et al. , 1989 Richardson et al. 1988; Treumann et al. 1997) as well as other unidentified glycoproteins (Güther et al. 2006 ). In T. brucei strain 427, used in this study, the parasites contain (per diploid genome) two copies of the GPEET1 gene, encoding a procyclin with 6 Gly-Pro-Glu-Glu-Thr repeats; one copy each of the EP1-1 and EP1-2 genes, encoding EP1 procyclins with 30 and 25 Glu-Pro repeats, respectively; two copies of the EP2-1 gene, encoding EP2 procyclin with 25 Glu-Pro repeats; and two copies of the EP3-1 gene, encoding EP3 procyclin with 22 Glu-Pro repeats (Acosta-Serrano et al. 1999; Roditi and Clayton 1999) . The EP1 and EP3 procyclins contain a single N-glycosylation site, at the N-terminal side of the GluPro repeat domain, occupied exclusively by a conventional Endo-H-sensitive triantennary Man 5 GlcNAc 2 oligosaccharide (Treumann et al. 1997) . Neither EP2 nor GPEET procyclin is N-glycosylated but GPEET1 procyclin is phosphorylated on six out of seven Thr residues (Butikofer et al. 1999; Mehlert et al. 1999) . GPEET and EP procyclins contain similar glycosylphosphatidylinositol (GPI) membrane anchors, based on the ubiquitous ethanolamine-P-6Manα1-2Manα1-6Manα1-4GlcNα1-6PI core (Ferguson 1999) , where in this case, the phosphatidylinositol (PI) lipid is a 2-O-acyl-lyso-PI structure, substituted with large branched poly-N-acetyllactosamine structures that can terminate with α2-3-linked sialic acid residues (Ferguson et al. 1993; Treumann et al. 1997) .
The bloodstream form of T. brucei has a surface coat of 5 × 10 6 variant surface glycoprotein (VSG) homodimers . The VSG coat serves as a physical barrier to components of the host complement system and undergoes antigenic variation (Pays et al. 2004; Taylor and Rudenko 2006) . There are many VSG genes and each encodes a GPIanchored glycoprotein with one to three N-glycosylation sites . The cell line used in this study expresses VSG variant 221 (also known as MiTat1.2). VSG221 has a GPI anchor with the same core as the procyclins but with a dimyristoyl-PI component and carbohydrate side chains of between two and six Gal residues (Mehlert, Zitzmann, et al. 1998 ). VSG221 has two N-glycosylation sites: the Asn428 site, five residues from the GPI attachment site, is occupied mostly by Endo-H-sensitive oligomannose structures GlcNAc 2 ), whilst the Asn263 site is occupied by small Endo-H-resistant biantennary structures ranging from Man 3-4 GlcNAc 2 to GalGlcNAcMan 3 GlcNAc 2 (Zamze et al. 1991) .
Protein N-glycosylation in eukaryotes serves a wide variety of functions including signaling through interaction with lectins, protein stabilization, protease resistance, endocytic sorting functions, and protein folding (Varki 1993; Rudd and Dwek 1997; Helenius and Aebi 2004) . In eukaryotes, a precursor for N-glycosylation is built up in the endoplasmic reticulum (ER) on the lipid carrier dolichol pyrophosphate (Dol-PP) (Burda and Aebi 1999) . The glycan portion of this Dol-PP-oligosaccharide is transferred en bloc by the action of oligosaccharyltransferase (OST), generally during protein translation and sequestration into the lumen of the ER, to Asn residues within Asn-X-Ser/Thr sequons (Helenius and Aebi 2004) . Processing of the precursor structure by glycosidase and glycosyltransferase enzymes within the ER and Golgi apparatus generates the final set of mature structures (Kornfeld R and Kornfeld S 1985; Schachter 2000) .
In most eukaryotes, the mature precursor used by OST is Glc 3 Man 9 GlcNAc 2 -PP-Dol. However, genomic and experimental comparisons have shown that some lower eukaryotes do not possess all the ALG genes needed to make Glc 3 Man 9 GlcNAc 2 -PP-Dol and that they transfer smaller glycans to protein (Parodi 1993; Samuelson et al. 2005) . Differences in the compositions and donor specificities of eukaryotic OST complexes, which usually contain eight different subunits, have also been noted (Kelleher and Gilmore 2006; Kelleher et al. 2007) .
Seminal work by Parodi and colleagues on several trypanosomatid parasites (excluding T. brucei) showed that protein N-glycosylation in these organisms is aberrant (reviewed in Parodi 1993) . None of these organisms make Dol-P-Glc and so fail to make glucosylated Dol-PP-oligosaccharide precursors. The mature Dol-PP-oligosaccharide species used for transfer to protein vary according to species. For example, Trypanosoma conhorini, Trypanosoma dionisii, Leptomonas samueli, Herpetomonas samuelpessoai, and Herpetomonas muscarum utilize triantennary Man 9 GlcNAc 2 -PP-Dol; Crithidia fasciculata, Crithidia Harmosa, and Leishmania enriettii utilize biantennary Man 7 GlcNAc 2 -PP-Dol; Leishmania mexicana, Leishmania adleri, and Blastocrithidia culicus utilize biantennary Man 6 GlcNAc 2 -PP-Dol (Parodi et al. 1981; Parodi and QuesadaAllue 1982; Previato et al. 1986; de la Canal and Parodi 1987) ; and Trypanosoma cruzi, the causative agent of Chagas' disease in the Americas, utilizes Man 9 GlcNAc 2 -PP-Dol during most of its life cycle but uses both Man 9 GlcNAc 2 -PP-Dol and Man 7 GlcNAc 2 -PP-Dol in its bloodstream trypomastigote stage (Doyle et al. 1986 ).
In a recent study, we showed that wild-type bloodstream form T. brucei utilizes both Man 9 GlcNAc 2 -PP-Dol and Man 5 GlcNAc 2 -PP-Dol to glycosylate the major surface coat glycoprotein VSG221 and, uniquely, does so in a site-specific manner (Jones et al. 2005) . Thus, whereas Man 9 GlcNAc 2 -PPDol is used to glycosylate Asn428, Man 5 GlcNAc 2 -PP-Dol is used to glycosylate Asn263. In addition, characterization of VSG221 made by an α-glucosidase II null mutant showed that the Asn263-linked Man 5 GlcNAc 2 glycan serves exclusively on VSG221 as the acceptor for the parasite's unfolded glycoprotein glucosyltransferase (UGGT) (Jones et al. 2005) . We further speculated that Man 5 GlcNAc 2 is the obligate precursor of all Endo-H-resistant (i.e., small biantennary oligomannose and complex) structures whereas Man 9 GlcNAc 2 is the obligate precursor of all conventional Endo-H-sensitive (i.e., Man 5-9 GlcNAc 2 ) oligomannose structures.
To test and refine our model of site-specific N-glycosylation and N-glycan processing, we constructed bloodstream and procyclic form T. brucei null mutants of the TbALG3 gene and observed the effects of limiting the parasite to solely a Man 5 GlcNAc 2 -PP-Dol lipid-linked precursor.
Results

Identification and cloning of the TbALG3 gene
A BLASTp (Altschul et al. 1990 ) search of the geneDB T. brucei predicted proteins database with the predicted amino acid sequence of the yeast ALG3 gene (accession no. NP 009471) yielded a putative T. brucei Dol-P-Man-dependent α1-3 mannosyltransferase sequence encoded by gene Tb10.70.0260, referred to from now on as TbALG3. The genome strain of T. brucei (strain 927) is different from that used in this study (strain 427). The TbALG3 gene was, therefore, cloned and sequenced from strain 427. The consensus sequence (accession no. AM850907) has four single base polymorphisms compared to the strain 927 database sequence, resulting in only a single amino acid polymorphism (Y in place of C at position 278). Southern blot analysis using a TbALG3 ORF probe revealed a single fragment after restriction enzyme digestion by HindIII, SacII, MscI, PstI, and XhoI whereas BsrGI yielded two fragments as it cuts the gene in the center of the gene (supplementary Figure S1 ). These data indicate that the TbALG3 gene is present as a single copy per haploid genome.
The predicted 46.4 kDa TbALG3 multispanning membrane protein has 26.2%, 33.4%, 33.7%, and 34.7% identity with the Saccharomyces cerevisiae, Mus musculus, Drosophila melanogaster, and Arabidopsis thaliana ALG3 sequences, respectively. The TbALG3 protein sequence conforms to that of a member of the α3,4-mannosyltransferase superfamily composed of dolichol cycle ALG3 α3-mannosyltransferases and GPI biosynthesis PIG-M α4-mannosyltransferase sequences (Oriol et al. 2002) . Based on conserved amino acid motifs, TbALG3 can further be distinguished as an ALG3-type α3-mannosyltransferase (Oriol et al. 2002) (Figure 1 ). This confirms that the sequence patterns described in Oriol et al. (2002) for discriminating ALG3 genes from related sequences can be extended to this ancient and highly divergent eukaryote. The TbALG3 sequence contains, like those of S. cerevisiae, D. melanogaster and M. musculus, a putative C-terminal ER retention signal.
Genes encoding proteins similar to TbALG3 were also found in the T. cruzi (gene Tc00.1047053510187.404) and Leishmania major (gene LmjF36.2040) databases with 48.5% and 44.5% predicted amino acid identity to TbALG3, respectively. Interestingly, the L. major sequence has 8-and 16-amino-acid inserts that are absent form the T. brucei and T. cruzi sequences.
Creation of TbALG3 null mutants
The two TbALG3 alleles were sequentially replaced by homologous recombination (Wirtz et al. 1999) with genes encoding puromycin acetyltransferase (PAC) followed by hygromycin phosphotransferase (HYG), for bloodstream form T. brucei, or PAC followed by blasticidin deaminase (BSD), for procyclic form T. brucei. Drug resistant clones were selected and characterized by Southern blotting of HindIII-and SacIIdigested genomic DNA with a TbALG3 ORF probe followed Oriol et al. (2002) , are common to the α3,4-mannosyltransferase superfamily and that define the ALG3 α3-mannosylatransferase family, respectively. The C-terminal sequences in bold italics are putative ER-retention signals by a β-tubulin probe, to ensure equal loading. A representative blot for one of the bloodstream form TbALG3 null mutants ( TbALG3::PAC/ TbALG3::HYG) is shown in Figure 2 .
The TbALG3 gene is nonessential to bloodstream form and procyclic form T. brucei
The in vitro growth rates of the TbALG3 null mutants of both life-cycle stages were indistinguishable from their parental cell lines (supplementary Figure S2) . Similarly, scanning electron micrographs of the TbALG3 null mutants of both life-cycle stages were indistinguishable from their parental cell lines (supplementary Figure S3) . Furthermore, bloodstream form TbALG3 null mutants were infective to mice and procyclic form TbALG3 null mutants were infective to tsetse flies, although the infectivity may have been marginally reduced (Figure 3 ). From these data we conclude that TbALG3 is a nonessential gene to the procyclic form and the disease-causing bloodstream form of T. brucei.
TbALG3 encodes a dolichol cycle α3-mannosyltransferase
Previous studies on dolichol-linked oligosaccharides and protein N-glycosylation in T. brucei have noted that although bloodstream form T. brucei make and utilize Man 9 GlcNAc 2 -PP-Dol (Zamze et al. 1991; Jones et al. 2005) , the steady-state levels of species larger than Man 5 GlcNAc 2 -PP-Dol are extremely low in this life-cycle stage (Low et al. 1991) . On the other hand, the Man 6 GlcNAc 2 -PP-Dol to Man 9 GlcNAc 2 -PP-Dol species are easier to observe in GDP-[ 3 H]Man labeling experiments using the procyclic form cell-free system (Low et al. 1991; Leal et al. 2004) . For this reason, we utilized procyclic form cell-free systems to assess the metabolic lesion caused by deletion of both TbALG3 alleles. Washed membranes (cell-free systems) prepared from wildtype and TbALG3 null mutant procyclic form trypanosomes were incubated UDP-GlcNAc and GDP-[ 3 H]Man, which labels both GPI and dolichol-PP-linked oligosaccharide precursors and their biosynthetic intermediates . To selectively analyze the dolichol-PP-linked oligosaccharide species, the labeled glycolipids were treated with mild acid and partitioned between butan-1-ol and water. The mild acidlabile pyrophosphate bonds of the Dol-PP-oligosaccharides result in the recovery of their radiolabeled free oligosaccharides in the aqueous phase, whereas the mild acid stable radiolabeled GPI species partition into the butan-1-ol phase. Following reduction of the radiolabeled free oligosaccharides with sodium borohydride and desalting, the resulting oligosaccharide alditols were analyzed by high-performance thin layer chromatography (HPTLC) and fluorography alongside authentic sodium borotritiide-reduced oligosaccharide alditol standards ( Figure 4A ). The fluorograph clearly shows that, as expected, the TbALG3 null mutant cell-free system is unable to produce oligosaccharides larger than Man 5 GlcNAc 2 . The radiolabeled free oligosaccharide alditols were further analyzed before and after digestion with Aspergillus saitoi Manα1-2Man-specific α-mannosidase (ASAM) ( Figure 4B ). The digestion patterns are consistent with the Man 5 GlcNAc 2 structure being Manα1-6(Manα1-2Manα1-2Manα1-3)Manβ1-4GlcNAcβ1-4GlcNAc, as summarized in Figure 4C .
Together, these data provide clear evidence that the largest Dol-PP-linked oligosaccharide made by the TbALG3 null mutant is a biantennary Man 5 GlcNAc 2 species and confirm that the TbALG3 gene encodes a α1-3 mannosyltransferase responsible for the conversion of Manα1-6(Manα1-2Manα1-2Manα1-3)Manβ1-4GlcNAcβ1-4GlcNAc-PP-Dol (Man 5 GlcNAc 2 -PPDol) to Manα1-3Manα1-6(Manα1-2Manα1-2Manα1-3)Man-β1-4GlcNAcβ1-4GlcNAc-PP-Dol (Man 6 GlcNAc 2 -PP-Dol).
Procyclin N-glycosylation is affected in TbALG3 null mutant procyclic form T. brucei
Procyclins were extracted from wild-type and TbALG3 null trypanosomes by differential solvent extraction and octylSepharose hydrophobic interaction chromatography. The proteins were first analyzed by SDS-PAGE and periodate-Schiff staining for carbohydrate. There was a small but perceptible downward shift in the apparent molecular weight range of the intact procyclins in the TbALG3 null mutants compared to those in the wild type ( Figure 5 , lanes 1 and 3), whereas the two samples appeared similar after peptide N-glycosidase-F (PNGaseF) treatment ( Figure 5 , lanes 2 and 4).
To gain a more detailed insight, procyclins from wild-type and TbALG3 null mutant cells were treated in three different ways, as described in Acosta-Serrano et al. (1999) and Leal et al. (2004) , and analyzed by negative-ion mode MALDI-TOF. The three treatments were as follows: (i) dephosphorylation with cold aqueous HF alone (aq. HF), to remove their heterogeneous GPI anchors and reveal the masses of their full amino acid sequence plus N-glycans; (ii) dephosphorylation with cold aqueous HF followed by de-N-glycosylation with PNGaseF (aq. HF + PNGaseF), to reveal the masses of their full amino acid sequences; (iii) dephosphorylation with cold aqueous HF followed by mild acid hydrolysis of Asp-Pro peptide bonds with trifluoroacetic acid (aq. HF + TFA), to reveal the masses of their diagnostic C-terminal peptide domains. The aforementioned treatments and their products are summarized at the top of Figure 6 and Table I and the MALDI-TOF spectra are shown in Figure 6A -F.
The aq. HF/TFA data are the simplest to interpret, since they show the diagnostic C-terminal domain peptide fragments that define which of the procyclin variants are present in the sample (Acosta-Serrano et al. 1999) . From these data, we can see that the wild-type cells are expressing a mixture of EP3, EP1-2 and EP1-1 procyclins, whereas the TbALG3 null mutant is expressing only EP3 and EP1-2 ( Figure 6A and B). Such changes in procyclin expression are known in procyclic form T. brucei (Treumann et al. 1997; Morris et al. 2002; Vassella et al. 2004 ).
The aq. HF/PNGaseF data gave the expected result for the wild-type procyclins, i.e., the EP3, EP1-2, and EP1-1 full-length peptides were observed ( Figure 6C ). However, the TbALG3 null mutant data were unusual in that, although the EP3 fulllength peptide is clearly seen (at m/z 8489), the majority of the EP1-2 procyclin was observed as homodimers at m/z 18496 or as EP1-2/EP3 heterodimers at m/z 17777 ( Figure 6D ). A trace of EP3 homodimer is also seen at m/z 177041. Why the procyclins from the TbALG3 null mutant, and in particular EP1-2, should have this propensity to appear as dimers by MALDI-TOF is unclear. None of the procyclins have cysteine residues, ruling out disulfide formation.
The aq. HF only data gave the expected result for the wildtype procyclins, i.e., the EP3, EP1-2, and EP1-1 full-length peptides plus conventional triantennary Man 5 GlcNAc 2 N-linked glycans were observed at m/z 9707, 10417, and 11519, respectively ( Figure 6E ). On the other hand, the aq. HF only data for the TbALG3 null mutant procyclins were strikingly different. In this case, a major ion at m/z 8492, corresponding to non-Nglycosylated EP3 procyclin was seen together with a cluster of three ions at m/z 9384, 9748, and 10119 that would correspond to EP3 procyclin containing Hex 3 HexNAc 2 , Hex 4 HexNAc 3 , and S Manthri et al. Fig. 6 . The MALDI-TOF mass spectra of treated wild-type and TbALG3 null mutant procyclins. Procyclins from wild-type cells (panels A, C, and E) and TbALG3 null mutant cells (panels D, E, and F) were analyzed by negative-ion MALDI-TOF mass spectrometry after treatment with aq. HF and mild acid (panels A and B), aq. HF and PNGaseF (panels C and D), and aq. HF alone (panels E and F). A schematic representation of the products of these treatments for wild-type EP1 procyclin is shown above the spectra. 2+ , respectively, were selected and subjected to collision-induced dissociation; the resulting production spectra contained intense m/z 486 ions, characteristic of N-acetyllactosamine (LacNAc) containing species ( Figure 7B , C). The lack of product ion at m/z 935 in Figure 7B , corresponding to a LacNAc 2 fragment ion, suggests that the Hex 5 HexNAc 4 species is a conventional Galβ1-4GlcNAcβ1-2Manα1-6(Galβ1-4GlcNAcβ1-2Manα1-3)Manβ1-4GlcNAcβ1-4GlcNAc (NA2-type) complex structure with one LacNAc unit on each branch.
In summary, these data show that whereas wild-type procyclic form T. brucei normally transfer Man 9 GlcNAc 2 oligosaccharides to their procyclin glycoproteins and process these to conventional triantennary Man 5 GlcNAc 2 oligomannose structures (Treumann et al. 1997; Acosta-Serrano et al. 1999) , there is significant under-N-glycosylation and aberrant processing to biantennary complex structures when biantennary Man 5 GlcNAc 2 -PP-Dol is the only donor available to the OST(s) present in that life-cycle stage.
VSG N-glycosylation is affected in TbALG3 null mutant bloodstream form T. brucei VSG glycoprotein was purified (Cross 1984) in its GPI-specific phospholipase C (GPI-PLC) cleaved soluble form (sVSG) (Ferguson et al. 1985 ) from wild-type and TbALG3 null mutant cells. Analysis by SDS-PAGE and Coomassie blue staining showed that whereas sVSG prepared from the wild-type cells appeared as a single ∼54 kDa band, sVSG prepared from the TbALG3 null mutant appeared as a doublet (Figure 8 ). To assess whether this change in the VSG pattern was due to changes in glycosylation, the wild-type and TbALG3 null mutant sVSGs were analyzed by mass spectrometry.
First, the upper and lower bands of the TbALG3 null mutant sVSG were excised separately from a gel, digested with trypsin, and the resulting peptides were analyzed by MALDI-TOF/TOF. Both bands were clearly identified as VSG221 (data not shown), the same VSG variant as the wild-type cells, suggesting that the differences in the SDS-PAGE pattern are indeed due to the difference in posttranslational modifications of the same sVSG variant.
Next, the positive-ion ES-MS spectra of the intact glycoproteins were collected and deconvolved using a Bayesian protein reconstruction method. The wild-type sVSG spectrum ( Figure 9A ) was the same as that described previously for this sVSG variant (Jones et al. 2005; Urbaniak et al. 2006 ) and the compositions of the isobaric glycoforms, resulting from structural heterogeneity at the two N-glycosylation sites (Zamze et al. 1991) and in the GPI anchor , are described in Table II . The TbALG null mutant sVSG spectrum ( Figure  9B ) showed two groups of sVSG glycoforms, consistent with the SDS-PAGE result. The lower molecular weight group of glycoforms has masses consistent with the C-terminal Asn428 N-glycosylation site being unoccupied (Table II) . The higher molecular weight group of glycoforms, with both N-glycosylation sites occupied, has significantly higher N-acetylhexosamine to hexose ratios than the wild-type glycoforms, suggesting that the N-glycans contain LacNAc structures at one or both sites (Table II) . These data provided the first direct evidence that deletion of the TbALG3 gene affects VSG glycosylation.
Wild-type and TbALG3 null mutant sVSG were also prepared from trypanosomes that had been grown in the presence of a cocktail of α-mannosidase inhibitors (kifunensine, swainsonine, and deoxymannojirimycin that, between them, can inhibit all known ER and Golgi α-mannosidase activities) and these Fig. 9 . sVSG221 glycoform analysis by ES-MS. Samples of sVG221 from wild-type cells (panels A and C) and TbALG3 null mutant cells (panels B and D) grown the absence (panels A and B) or presence (panels C and D) of α-mannosidase inhibitors were analyzed by the positive-ion ES-MS and deconvolved spectra of the various isobaric glycoforms were generated. The compositions of these glycoforms are given in Table II. too were analyzed by ES-MS. This experiment was performed to confirm that the TbALG3 null mutant cannot transfer structures larger than Man 5 GlcNAc 2 that might then be processed down to Man 5 GlcNAc 2 by ER and/or Golgi α-mannosidases. The spectrum for the wild-type sVSG made in the presence of α-mannosidase inhibitors (MI) is similar to that previously described (Jones et al. 2005 ) with a general upward shift in glycoform size (Table II) due to substantial inhibition of α-mannosidase trimming of both the internal and C-terminal N-glycans ( Figure 9C ). The effect of MI on the TbALG3 null mutant sVSG was more complex, with a general increase in size for the low molecular weight group of glycoforms and a general decrease in size for the high molecular weight group of glycoforms ( Figure 9D ).
Novel aspects of N-glycosylation in Trypanosoma brucei
To ascertain more precisely the changes induced by the deletion of TbALG3 gene (and the effects of MI) on sVSG glycosylation, the N-glycans present at each of the two N-glycosylation sites and the GPI-anchor structures attached to the C-terminal serine residue were determined by ES-MS and ES-MS/MS analysis of Pronase digests. The Pronase glycopeptides were also reanalyzed after digestion with Manα1-2Man-specific Aspergillus saitoi α-mannosidase (ASAM).
From these data, summarized in Figure 10 , we can conclude that (i) glycosylation of the internal Asn263 residue is largely unchanged by the deletion of the TbALG3 gene. (ii) The dramatic increase in the Man 5 -containing glycans attached to the Asn263 site when wild-type and TbALG3 null VSG is made in the presence of the α-mannosidase inhibitor cocktail confirms that biantennary Man 5 GlcNAc 2 is the precursor of all of the structures found at this glycosylation site. (The presence of some smaller structures suggests that the α-mannosidase block was slightly incomplete in these experiments.) (iii) Although ASAM digestion converts most of the biantennary Man 5 GlcNAc 2 and Man 4 GlcNAc 2 structures to Man 3 GlcNAc 2 , some of the structures at Asn263 contain six Hex residues that are not digested by ASAM. This suggests that the Hex 6 HexNAc 2 glycan attached to Asn263 is Manα1-6(Glcα1-3Manα1-2Manα1-2Manα1-3)Manβ1-4GlcNAcβ1-4GlcNAc. This glycan species that occupies about 10% of the Asn263 site in the wild-type VSG has not previously been noted in mature VSG molecules. On the other hand, similar residual αGlc is quite abundant in the N-linked glycans of L. major and L. mexicana promastigote surface protease glycoprotein, also known as gp63, (Olafson et al. 1990; Ilg et al. 1994) . (iv) The most striking change in VSG glycosylation upon TbALG3 deletion is seen at the C-terminal N-glycosylation site where the mixture of conventional triantennary oligomannose Man 5−9 GlcNAc 2 glycans is replaced by complex biantennary structures. (v) Some a Protein M r is based on the amino acid sequence of the VSG221 precursor (accession no. P26332) minus residues 1-27 (signal peptide) and 460-476 (GPI attachment signal peptide) and allows for four disulfide bonds (M r = 46,284). b Components specific to the GPI anchor and common to all glycoforms; I-cP myo-inositol-1,2 cyclic phosphate; EtNP, ethanolamine phosphate. c The most abundant glycoform of wild-type sVSG221 is expected to contain a GPI anchor of composition of Man3Gal5, a C-terminal N-linked glycan of Man9GlcNAc2 and an internal N-linked glycan of Man3GlcNAc2; i.e., HexNAc (GlcNAc) = 4 and Hex (Man + Gal) = 20. The molecular weights of different glycoforms of sVSG221 were calculated according to the indicated compositions. The −, trace, +, ++, +++ scores indicate the relative abundances of those glycoforms observed in sVSG preparations of wild-type and TbALG3 null mutants with and without mannosidase inhibitors (MI).
of the VSG molecules in the TbALG3 null mutant fail to be N-glycosylated at the C-terminal Asn428 site. (vi) When grown in the presence of α-mannosidase inhibitors, the complex structures at Asn428 in the TbALG3 null mutant are replaced by atypical hybrid structures, suggesting that the usual processing of biantennary Man 5 GlcNAc 2 after transfer to Asn428 is the addition of a LacNAc unit to the α1-6 arm of Man 5 GlcNAc 2 , either after or during the removal of the two α1-2-linked Man residues from the α1-3 arm, and the subsequent addition of up to a further 3 LacNAc units. If the two outer α1-2-linked Man residues on the α1-3 arm are retained (as in the VSG from α-mannosidase inhibitor treated cells), elaboration appears to be limited to the addition of a single LacNAc unit to the α1-6 arm. (vii) There are no qualitative and only minor quantitative changes to the VSG GPI anchor glycan side chains in the TbALG3 null mutant.
Analysis of other glycoproteins by lectin blotting
As described above, sVSG analysis by mass spectrometry showed that the glycans at the C-terminal (Asn428) N-glycosylation site were changed from oligomannose type to complex type by deletion of the TbALG3 gene, resulting in an increase in the number of terminal galactose residues on the glycopeptides. We wanted to investigate other glycoproteins to see if this shift from oligomannose-type to complex-type glycans was a general effect of TbALG3 deletion. Wild-type and TbALG3 null mutant bloodstream form trypanosomes were purified and subjected to osmotic shock, which leads to the GPI-PLC-mediated release of about 90% of cellular VSG as sVSG (Cross 1984; Ferguson et al. 1985) . The remaining VSG-depleted wild-type and TbALG3 null mutant cell ghosts were washed and solubilized in 2% SDS, 8 M urea (Atrih et al. 2005 ) and equivalent amounts were subjected to SDS-PAGE and Western blotting with horseradish peroxidase conjugated concanavalin A (ConA) in the presence and absence of α-methyl-mannose inhibitor. The TbALG3 null mutant lysate clearly binds less well to ConA than the wild-type lysate ( Figure 11A ). ConA is a lectin that binds with highest affinity to oligomannose and hybrid glycans containing a Manα1-3(Manα1-6)Manα1-motif and less well to complex biantennary-type glycopeptides (Ohyama et al. 1985 ; Brewer and Bhattacharyya 1986; Naismith and Field 1996) . The reduction in ConA binding to the TbALG3 null mutant glycoproteins is consistent with the expected general ablation of oligomannose (i.e., triantennary Man 5−9 GlcNAc 2 ) structures. The same lysates were subjected to blotting with ricin, a lectin that binds terminal Gal residues, except this time approximately three times more wild type than TbALG3 lysate was loaded. Taking this into account, it can be seen that the TbALG3 null mutant lysate glycoproteins have significantly greater ricin binding capacity ( Figure 11B ).
Taken together, these data are consistent with a general upregulation of Gal-terminating complex glycans at the expense of conventional oligomannose structures in the TbALG3 null bloodstream form trypanosomes.
Discussion
Deletion of the TbALG3 gene in bloodstream and procyclic form T. brucei has no significant effect on their growth, morphology or the infectivity of the parasite to mice and tsetse flies, respectively. We may, therefore, conclude that the Dol-PMan-dependent α1-3 mannosyltransferase encoded by TbALG3 is not useful drug target against African trypanosomiasis. However, the retention of ALG3, ALG12, and ALG9 genes in T. brucei indicates that the ability to make Man 9 GlcNAc 2 -PP-Dol presumably has some selective advantage for the organism and we cannot rule out a role for TbALG3 in other life-cycle stages or in parasite differentiation processes.
The glycosylation phenotypes of the null mutant parasites supports the model of site-selective N-glycosylation, originally proposed by Bangs et al. (1988) and elaborated in Jones et al. (2005) . That model predicts that preventing the synthesis of dolichol cycle intermediates beyond Man 5 GlcNAc 2 -PP-Dol should have little or no effect on the glycosylation and subsequent processing of the Asn263 site of VSG221, since this site normally receives Man 5 GlcNAc 2 from Man 5 GlcNAc 2 -PP-Dol in wild-type cells. This is indeed the case, apart from an increase (from approximately 10 to 19 mol%) in Glc 1 Man 5 GlcNAc 2 at this site. The latter effect may be due to the aberrantand underglycosylation that is observed at the C-terminal Asn428 site, perhaps causing greater activity of UGGT in the UGGT/calreticulin/α-glucosidase II-mediated refolding and quality control cycle.
The underglycosylation of the Asn428 site of VSG221 in the TbALG3 null mutant is significant because it provides evidence that the OST(s) that normally recognize this sequon have a preference for Man 9 GlcNAc 2 -PP-Dol and that, when this donor is absent, they utilize Man 5 GlcNAc 2 -PP-Dol relatively poorly. Exactly the same phenomenon is seen in the procyclic form of the parasite, where the procyclins that normally receive Man 9 GlcNAc 2 are similarly underglycosylated. These observations support a refined model (Figure 12 ) whereby two different classes of OST activity exist in T. brucei: one, that we will refer to as TbOST-1, that recognizes sites like Asn263 in VSG221 and preferentially utilizes Man 5 GlcNAc 2 -PP-Dol and another, that we will refer to as TbOST-2, that recognizes sites like Asn428 in VSG221 and those of EP3 and EP1-2 procyclin and preferentially utilizes Man 9 GlcNAc 2 -PP-Dol. The genome sequencing supports this model in so far as T. brucei has three OST catalytic subunit STT3 genes (although, intriguingly, it lacks candidate genes for all other known OST subunits [Kelleher and Gilmore 2006] ). The three TbSTT3 genes are found in a tandem array at the end of chromosome 5 and two of them encode almost identical proteins. We speculate that the unique TbSTT3 utilizes exclusively either Man 5 GlcNAc 2 -PP-Dol or Man 9 GlcNAc 2 -PPDol and that one or both of the two similar TbSTT3s utilize the other donor. In this model, the different VSG glycosylation sites are predicted to recruit the appropriate TbOST, and thus dictate the glycan transferred to that site. The fact that posttranslational N-glycosylation of Endo-H-sensitive (but not Endo-H-resistant) sites has been observed for two different VSG variants (Ferguson et al. 1986; Bangs et al. 1988 ) also provides support for this model and further suggests that TbOST-1 is associated with co-translational glycosylation whereas TbOST-2 is associated with posttranslational glycosylation. Testing of this revised model awaits the construction and characterization of TbSTT3 mutants and a (glyco)proteome-wide analysis of the occupancy of T. brucei N-glycosylation sites with Endo-H-sensitive and resistant glycans to identify the flanking peptidic features that are recognized by TbOST-1 and TbOST-2. This work is currently in progress in our laboratory.
The other key result for this study is the processing of Man 5 GlcNAc 2 (i.e., aberrantly transferred to "Man 9 GlcNAc 2 -sites" in the TbALG3 null mutants) to complex biantennary structures on both Asn428 of VSG221 and the N-glycosylation sites of EP3 and EP1-2 procyclin. This supports the notion (Jones et al. 2005 ) that Man 5 GlcNAc 2 is destined for processing into complex structures and, importantly, suggests that there is nothing inherent in those sites that prevent their processing to complex structures.
This, in turn, begs the question as to why sites that normally receive Man 9 GlcNAc 2 can only be processed to other Endo-H-sensitive oligomannose structures (i.e., triantennary Man 5-9 GlcNAc 2 ). The answer may lie partly in the absence of a putative T. brucei Golgi α-mannosidse II gene. Golgi α-mannosidse II normally removes the α1-3 and α1-6-linked Man residues from the 6-arm of the trimannosyl core to provide a substrate for elaboration by GnT-II into complex Novel aspects of N-glycosylation in Trypanosoma brucei Fig. 12 . Model of the site-specific protein N-glycosylation and N-glycan processing in T. brucei. Panel A illustrates the proposed existence of two distinct oligosaccharyltransferase activities, one (TbOST-1) that cotranslationally transfers Man 5 GlcNAc 2 to specific glycosylation sites (e.g., Asn263 of VSG221) and the other (TbOST-2) that preferentially transfers Man 9 GlcNAc 2 posttranslationally to any remaining sites (e.g., Asn428 of VSG221 and procyclin sites). Panel B illustrates the processing of Man 9 GlcNAc 2 and Man 5 GlcNAc 2 in VSG221 and procyclin in wild-type trypanosomes. The structures in boxes are those that have been experimentally observed at the respective glycosylation sites in the mature glycoproteins. The inability of T. brucei to process Man 9 GlcNAc 2 beyond triantennary Man 5 GlcNAc 2 is thought to be due to unusual specificity of TbGnT-I and the absence of Golgi α-mannosidase II. Panel C illustrates the processing of Man 5 GlcNAc 2 in VSG221 and procyclin in TbALG3 null mutant trypanosomes. Structures in boxes are those that have been experimentally observed at the respective glycosylation sites in the mature glycoproteins. The +/− symbol indicates inefficient oligosaccharide transfer of Man 5 GlcNAc 2 by TbOST-2 that normally transfers Man 9 GlcNAc 2 . The processing of Man 5 GlcNAc 2 to complex biantennary structures at Asn428 of VSG221 supports the model that sites that receive Man 5 GlcNAc 2 are destined to be processed to complex structures in T. brucei.
structures (Schachter 2000) . However, this alone does not explain why GnT-I activity could not convert triantennary Man 5 GlcNAc 2 into conventional hybrid structures. However, whereas eukaryotic GnT-I enzymes typically work on triantennary Man 5 GlcNAc 2 , analysis of ConA-resistant procyclic mutants (Hwa and Khoo 2000) strongly suggest that TbGnT-I can only operate on Man 1-3Man 1-6(Man 1-3)-Manβ1-4GlcNAcβ1-4GlcNAc (Man 4 GlcNAc 2 ) and Man 1-6(Man 1-3)Manβ1-4GlcNAcβ1-4GlcNAc (Man 3 GlcNAc 2 ) structures. Combining these observations leads to the model shown in Figure 12 that satisfies most or all of the current experimental data. For example, it explains why the effects of TbALG3 and TbALG12 deletion are similar with respect to procyclin underglycosylation (because TbOST2 prefers Man 9 GlcNAc 2 -PP-Dol) yet different with respect to the final processed glycan structures (Leal et al. 2004 ). In the TbALG12 null mutant (and in ConA-resistant mutants), the procyclinlinked Man 7 GlcNAc 2 structure can be processed by ER α1-2 mannosidases to Man 1-3Man 1-6(Man 1-3)Manβ1-4Glc-NAcβ1-4GlcNAc (Man 4 GlcNAc 2 ) and further elaborated on the 3-arm of the trimannosyl core by a LacNAc unit (AcostaSerrano et al. 2000; Hwa and Khoo 2000; Leal et al. 2004) whereas in the TbALG3 mutant, the Manα1-6(Manα1-2Manα1-2Manα1-3)Manβ1-4GlcNAcβ1-4GlcNAc (Man 5 GlcNAc 2 ) structure attached to procyclin is processed by ER α1-2 mannosidases to Manα1-6(Manα1-3)Manβ1-4GlcNAcβ1-4GlcNAc (Man 3 GlcNAc 2 ) that can receive LacNAc units on both arms of the trimannosyl core.
In summary, the revised model presented here serves to highlight fundamental differences in the mechanisms of protein N-glycosylation and glycan processing between T. brucei and its mammalian hosts. Further study may reveal therapeutically exploitable differences.
Materials and methods
Cultivation of trypanosomes
Bloodstream form T. brucei strain 427 that has genetically been modified to express T7 polymerase and the tetracycline repressor protein, referred to as wild type for convenience, were cultured in the HMI-9 medium (Hirumi H and Hirumi K 1994) with the addition of 2.5 µg/mL G418 at 37
• C in a 5% CO 2 incubator. For some experiments the trypanosomes were grown for 48 h in the presence of a cocktail of α-mannosidase inhibitors as previously described (Jones et al. 2005) . Procyclic T. brucei strain 427 clone 29.13, referred to as wild-type cells, were cultured in SDM-79 (Brun and Schonenberger 1979) in the presence of 15% fetal bovine serum (FBS) and 7.5 mg/L haemin (Wirtz et al. 1999) together with 15 µg/mL G418 and 50 µg/mL hygromycin in a 28
• C incubator. The concentrations of drugs used for the selection of mutants were 4 µg/mL for hygromycin and 0.1 µg/ mL for puromycin for bloodstream form cells and 10 µg/ mL for blasticidin and 1 µg/mL for puromycin for procyclic form cells.
DNA manipulation
Plasmid DNA was purified using Miniprep or Maxiprep kits (Qiagen, Crawley, UK). Gel extraction and cleanup were performed with a Qiaquick kit (Qiagen). Genomic DNA was isolated from ∼5 × 10 8 bloodstream form and procyclic form cells using DNAzol (Helena Biosciences, Gateshead, UK).
Cloning and sequencing of the TbALG3 ORF
The 1214 bp ORF was amplified by PCR from genomic DNA using Pfu polymerase with 5 -CCCAAGCTTATGGAGTAT-CGGTGGCTG-3 forward and 5 -CGGGATCCCTACTTTC-CCCTTTTCACAG-3 reverse primers using the cycling parameters 94
• C for 5 min, 30 cycles of 94
• C for 30 s, 52
• C for 2 min, and 68
• C for 30 s, followed by 10 min extension at 68 • C. Four separate PCR products were purified, cloned into pCR-Blunt II TOPO (Invitrogen, Paisley, UK), and sequenced twice in both directions.
Gene replacement constructs
To generate the T. brucei gene replacement cassettes, 500 bp 5 -UTR and 500 bp 3 -UTR immediately adjacent to the TbALG3 ORF were amplified by PCR from T. brucei genomic DNA using Pfu polymerase with primers 5 -ATAAGAA-TGCGGCCGCTCATTTTTTTGATTGGTTACCTC-3 and 5 -GTTTAAACTTACGGACCGTCAAGCTTTCCTCACTGGT-GGGGAC-3 for the 5 -UTR, and primers 5 -GACGGT-CCGTAAGTTTAAACGGATCCGCAACCGGAACAAGTG-ATC-3 and 5 -ATAAGAATGCGGCCGCCCCCGACGCGAC-CCAA-3 for the 3 -UTR. The products from the above PCR reactions were joined together in a further PCR via a short BamHI-PmeI-HindIII linker region contained within the primers and a NotI site (underlined) at each end. This PCR product was ligated into pGEM-5Zf(+) (Promega) via the NotI sites. Antibiotic resistance markers were ligated between the BamHI and HindIII restriction sites, to produce constructs containing puromycin acetyltransferase (PAC), hygromycin phosphotransferase (HYG) and blasticidin deaminase (BSD) resistance genes. After sequencing, plasmids were purified and digested with NotI. The digestion products were precipitated and washed in 70% ethanol, dissolved in sterile distilled water, and used for electroporation to sequentially replace TbALG3 alleles by homologous recombination (Wirtz et al. 1999) .
Southern blotting
T. brucei genomic DNA, prepared from 100 mL cultures of bloodstream form and 10 mL cultures of procyclic form cells, was digested with the various restriction enzymes overnight and resolved on a 0.8% agarose gel and transferred on to a Hybond-N positively charged membrane (GE Healthcare, Amersham, UK). The membrane was hybridized overnight in ULTRA-HYB (Ambion) at 42
• C with the fluorescein-labeled TbALG3 ORF probe (CDP-Star random prime labeling kit, GE Healthcare). After two 20-min washes (once with 2 × SSC, 0.1% SDS and once with 0.2 × SSC, 0.1% SDS) the probe was detected by using the CDP-Star detection system.
Tsetse fly infections
Pupae of Glossina morsitans were obtained from Institute of Zoology, Slovak Academy of Science (Bratislava, Slovakia). Newly hatched (teneral) flies were fed with an infected bloodmeal, which consisted of 10 7 parasites mixed with washed defribinated horse blood (containing 10% FBS). Infected flies were fed with bloodmeals every 2-3 days. After 2 weeks or 3 weeks, midguts were isolated from infected flies and disrupted by mechanical force in cold SDM-79 containing 10% FBS. Isolated parasites from individual midguts were kept on ice until counted on a haemocytometer.
Preparation and radiolabeling of trypanosome cell free systems
Trypanosome membranes were prepared from wild-type cells and TbALG3 null mutant cells as described by Masterson et al. (1989) . Cell lysates were thawed on ice and washed twice with a HKML buffer (50 mM HEPES, pH 7.4, 25 mM KCl, 5 mM MgCl 2 , 1 µg of leupeptin/mL, 0.1 mM TLCK) and resuspended at a concentration of 1 × 10 9 /mL in 2 × incorporation buffer (HKML buffer with 5 mM MnCl 2 and 1 mM DTT). The membranes (2 × 10 7 cell equivalents) were transferred to another tube containing GDP- [3,4- 3 H]Man and 2 mM UDPGlcNAc for 5 min at 30
• C. The reaction was chased with 1 mM nonradioactive GDP-Man for 20 min at 30
• C. Reactions were terminated by adding chloroform and methanol to reach a final CHCl 3 :CH 3 OH:H 2 O ratio of 10:10:3 (v/v/v) and sonicated in a sonicating water bath for 10 min. After overnight extraction, the chloroform/methanol/water extract was centrifuged and the supernatant dried under a stream of nitrogen and partitioned between butan-1-ol and water, as described in Acosta-Serrano et al. (2004) . The labeled glycolipid products were treated with 100 µL of 0.1 M TFA, 98
• C, 15 min, cooled on ice and extracted twice with butan-1-ol to remove labeled GPIs. The aqueous phase, containing the acid-released glycans from the Dol-PP-oligosaccharides, were dried under a stream of nitrogen and reduced with 100 µL of 0.5 M NaBH 4 , 3 h, room temperature. Excess reductant was destroyed by adding 100 µL 1 M acetic acid and the reduced labeled glycans were desalted by application to a column of 0.2 mL AG50 (H + form) and elution with 0.8 mL water. The eluate was freeze-dried and residual boric acid was removed by coevaporation (twice) with 250 µL methanol, 5% acetic acid and twice with 250 µL of methanol. Residual acetic acid was removed by coevaporation with 50 µL of toluene. The radiolabeled glycans were dissolved in 40% propanol and applied to silica gel 60 high-performance thin layer chromatography plates (Merck, Nottingham, UK) and developed with butan-1-ol/ethanol/water (4:3:3, v/v/v) . The plate was sprayed with En 3 Hance and [ 3 H]-labeled products were detected by fluorography by exposing the Kodak-X-Omat X-ray film at −80
• C.
Purification and MALDI-TOF analysis of procyclins
The procyclins were purified from 5 × 10 10 freeze-dried procyclic form trypanosomes by organic solvent extraction followed by octyl-Sepharose chromatography (Ferguson et al. 1993; Treumann et al. 1997; Mehlert et al. 1999) . Samples (approx. 250 pmole) of octyl-Sepharose-purified procyclins were dried and treated with 50 µL of ice-cold 50% aqueous hydrogen fluoride (aq. HF) for 24 h at 0
• C to cleave the GPI anchor ethanolamine-phosphate bond. Some preparations were further treated with 50 µL of 40 mM trifluoroacetic acid, 100
• C for 20 min to cleave Asp-Pro bonds and remove N-glycosylated N-termini. Some aq. HF-treated procyclin samples were deglycosylated with 15 units of peptide N 4 (N-acetyl-β-glucosaminyl) asparagine amidase F (PNGase F) (Roche, Burgess Hill, UK) in 2 µL of 0.25 M sodium phosphate buffer (pH 7.5). The samples were dried and redissolved in 5 µL of 0.1% trifluoroacetic acid and aliquots (1 µL) of each sample were mixed with 1 µL of 10 mg/mL α-cyano-4-hydroxycinnamic acid as the matrix acid in 50% acetonitrile, 0.1% trifluoroacetic acid and analyzed by linear-mode negative-ion MALDI-TOF on an ABI Voyager DE-STR instrument. The accelerating voltage was 25,000 V, and the grid voltage was set at 93% with an extraction time delay of 400 ns. Data were collected manually at 500 shots per spectrum with the laser intensity set at 2000 V.
sVSG isolation Soluble form VSG was isolated from 2 × 10 8 bloodstream form T. brucei cells as described in Cross (1975 Cross ( , 1984 . Briefly, cells were chilled on ice for 10 min, centrifuged at 2500 × g for 10 min, washed in an isotonic buffer and resuspended in 300 µL of 10 mM sodium phosphate buffer, pH 8.0, containing 0.1 mM TLCK, 1 µg/mL leupeptin, and 1 µg/mL aprotinin. After 5 min at 37
• C, the mixture was cooled on ice and centrifuged (14,000 × g, 5 min). The supernatant was applied to a small (0.2 mL) DE52 anion exchange column equilibrated in a 10 mM sodium phosphate buffer, pH 8.0 and eluted with 0.8 mL of the same buffer. The entire column eluate (containing about 100 µg sVSG) was concentrated and diafiltered with water on a Microcon YM-10 concentrator (Millipore, Watford, UK) and recovered in 100 µL of water.
ES-MS analysis of intact VSG
sVSG obtained from small scale VSG purification was diluted to ∼0.05 µg/µL in 50% methanol, 1% formic acid, loaded into nanotips (Micromass-type F). The positive-ion electrospray mass spectra were recorded on the ABI QSTAR-XL system with tip potential of 900 V and declustering potential of 60 V. Data were deconvolved by using the ABI Analyst software and using the Bayesian protein reconstruct program.
ES-MS and ES-MS/MS analysis of Pronase glycopeptides
Aliquots of sVSG (approximately 50 µg in 50 µL water) were mixed with 5 µL of 1 M ammonium bicarbonate and 10 µL of 1 mg/mL Pronase in 5 mM calcium acetate and incubated at 37
• C for 36 h. The Pronase glycopeptides were purified on Envicarb graphitized carbon microcolumns which were prepared as follows: the contents of an Envicarb cartridge (Supelco, Poole, UK) were suspended in methanol and a bed of approximately 20 µL of graphitized carbon was packed into a 100 µL C4 OMIX (Varian, Oxford, UK) pipette tip. The microcolumns were prepared by attaching them to a Gilson pipette, set at 100 µL, and pipetting up and down 10 times with 80% methanol, 1% formic acid; 60% methanol, 1% formic acid; and 1% methanol, 1% formic acid. The sample (10 µL of Pronase digest) was mixed with 90 µL of 1% methanol, 1% formic acid and applied to the microcolumn by pipetting up and down 20 times. The microcolumns were washed by pipetting up and down 20 times with 1% methanol, 1% formic acid. The pipette was reset to 50 µL and the glycopeptides eluted by pipetting up and down 20 times with 50 µL of 60% methanol, 1% formic acid. Aliquots of these samples were loaded into nanotips (Micromass-type F) and analyzed by ES-MS in positive-ion mode on an ABI Q-Star-XL instrument with tip and declustering potentials of 900 V and 60 V, respectively. The product ion spectra of selected ions were collected using collision energies of 30-60 V. The ES-MS spectra were processed using the Baysian peptide reconstruction program in the ABI Analyst software. After analysis, the
